Cargando…

Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer

BACKGROUND: Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after treatment for estrogen receptor positive (ER+ve), early-stage breast cancer. AET has proven effectiveness in reducing the risk of recurrence of breast cancer and mortality. However, adherence is known to be subo...

Descripción completa

Detalles Bibliográficos
Autores principales: Brett, Jo, Boulton, Mary, Watson, Eila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294163/
https://www.ncbi.nlm.nih.gov/pubmed/30587936
http://dx.doi.org/10.2147/PPA.S187692
_version_ 1783380687925018624
author Brett, Jo
Boulton, Mary
Watson, Eila
author_facet Brett, Jo
Boulton, Mary
Watson, Eila
author_sort Brett, Jo
collection PubMed
description BACKGROUND: Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after treatment for estrogen receptor positive (ER+ve), early-stage breast cancer. AET has proven effectiveness in reducing the risk of recurrence of breast cancer and mortality. However, adherence is known to be suboptimal with around 20% discontinuing by 2 years and up to 50% discontinuing by 5 years. Interventions are needed to support women taking AET after breast cancer. The aim of this study was to develop and pilot test an e-health app for this population. METHODS: Two focus groups (n=15) and five interviews were conducted with women following treatment for early-stage breast cancer to assess the likely acceptability of an e-health app and to inform the content (Phase I). Following development of a prototype e-health app, a simple heuristic usability test was completed by five women in order to identify any design usability problems (Phase II). A further 18 women used the app for 1 month between July and August 2016, after which they were interviewed by telephone to collect their experiences and views of the app (Phase III). RESULTS: The prototype e-health app included evidence-based information on effectiveness of AET, an electronic side-effects diary, a peer support forum, a repeat prescription reminder, suggested strategies for facilitating adherence and managing any side effects that occur, and a link to further evidence and useful organizations for further information and support. The app was received positively by women. Women found the app useful as it emphasized the importance of taking AET, helped them manage their side effects and provided details of support organizations, while offering empathy and exchange of suggestions for self-management strategies through the peer support forum. CONCLUSION: Overall, findings suggest that this novel e-health app has potential as a feasible medium for promoting adherence to AET. Future research should evaluate the efficacy of the app in supporting women and promoting adherence.
format Online
Article
Text
id pubmed-6294163
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62941632018-12-26 Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer Brett, Jo Boulton, Mary Watson, Eila Patient Prefer Adherence Original Research BACKGROUND: Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after treatment for estrogen receptor positive (ER+ve), early-stage breast cancer. AET has proven effectiveness in reducing the risk of recurrence of breast cancer and mortality. However, adherence is known to be suboptimal with around 20% discontinuing by 2 years and up to 50% discontinuing by 5 years. Interventions are needed to support women taking AET after breast cancer. The aim of this study was to develop and pilot test an e-health app for this population. METHODS: Two focus groups (n=15) and five interviews were conducted with women following treatment for early-stage breast cancer to assess the likely acceptability of an e-health app and to inform the content (Phase I). Following development of a prototype e-health app, a simple heuristic usability test was completed by five women in order to identify any design usability problems (Phase II). A further 18 women used the app for 1 month between July and August 2016, after which they were interviewed by telephone to collect their experiences and views of the app (Phase III). RESULTS: The prototype e-health app included evidence-based information on effectiveness of AET, an electronic side-effects diary, a peer support forum, a repeat prescription reminder, suggested strategies for facilitating adherence and managing any side effects that occur, and a link to further evidence and useful organizations for further information and support. The app was received positively by women. Women found the app useful as it emphasized the importance of taking AET, helped them manage their side effects and provided details of support organizations, while offering empathy and exchange of suggestions for self-management strategies through the peer support forum. CONCLUSION: Overall, findings suggest that this novel e-health app has potential as a feasible medium for promoting adherence to AET. Future research should evaluate the efficacy of the app in supporting women and promoting adherence. Dove Medical Press 2018-12-11 /pmc/articles/PMC6294163/ /pubmed/30587936 http://dx.doi.org/10.2147/PPA.S187692 Text en © 2018 Brett et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Brett, Jo
Boulton, Mary
Watson, Eila
Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title_full Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title_fullStr Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title_full_unstemmed Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title_short Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
title_sort development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294163/
https://www.ncbi.nlm.nih.gov/pubmed/30587936
http://dx.doi.org/10.2147/PPA.S187692
work_keys_str_mv AT brettjo developmentofanehealthapptosupportwomenprescribedadjuvantendocrinetherapyaftertreatmentforbreastcancer
AT boultonmary developmentofanehealthapptosupportwomenprescribedadjuvantendocrinetherapyaftertreatmentforbreastcancer
AT watsoneila developmentofanehealthapptosupportwomenprescribedadjuvantendocrinetherapyaftertreatmentforbreastcancer